Validation of the BARD scoring system in Polish patients with nonalcoholic fatty liver disease (NAFLD)
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1471-230X
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Validation of the BARD scoring system in Polish patients with nonalcoholic fatty liver disease (NAFLD) ; volume:10 ; number:1 ; day:28 ; month:6 ; year:2010 ; pages:1-6 ; date:12.2010
BMC gastroenterology ; 10, Heft 1 (28.6.2010), 1-6, 12.2010
- Creator
-
Raszeja-Wyszomirska, Joanna
- Contributor
-
Szymanik, Barbara
Ławniczak, Małgorzata
Kajor, Maciej
Chwist, Alina
Milkiewicz, Piotr
Hartleb, Marek
SpringerLink (Online service)
- DOI
-
10.1186/1471-230X-10-67
- URN
-
urn:nbn:de:1111-201607153960
- Rights
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:50 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Raszeja-Wyszomirska, Joanna
- Szymanik, Barbara
- Ławniczak, Małgorzata
- Kajor, Maciej
- Chwist, Alina
- Milkiewicz, Piotr
- Hartleb, Marek
- SpringerLink (Online service)
Other Objects (12)
"Endocrine NAFLD": a hormonocentric perspective of Non-Alcoholic Liver Disease (NAFLD) pathogenesis in HIV-infected patients
Korrelation von Apolipoprotein C3 und non-alcoholic fatty liver disease (NAFLD)
Indices to represent cross-sectional non-alcoholic fatty liver disease (NAFLD) and longitudinal NAFLD development during lifestyle interventions
Genetic and metabolic aspects of non-alcoholic fatty liver disease (NAFLD) pathogenicity
Plasmatic higher levels of homocysteine in Non-alcoholic fatty liver disease (NAFLD)
The Bard’s Tale
BARD
BARD
Association between PPARGC1A polymorphisms and the occurrence of nonalcoholic fatty liver disease (NAFLD)
Emerging role of nanotechnology in treatment of non-alcoholic fatty liver disease (NAFLD)
Do artificial sweeteners increase the risk of non-alcoholic fatty liver disease (NAFLD)?
Treatment of Nonalcoholic Fatty Liver Disease (NAFLD) in patients with Type 2 Diabetes Mellitus
"Endocrine NAFLD": a hormonocentric perspective of Non-Alcoholic Liver Disease (NAFLD) pathogenesis in HIV-infected patients
Korrelation von Apolipoprotein C3 und non-alcoholic fatty liver disease (NAFLD)
Indices to represent cross-sectional non-alcoholic fatty liver disease (NAFLD) and longitudinal NAFLD development during lifestyle interventions
Genetic and metabolic aspects of non-alcoholic fatty liver disease (NAFLD) pathogenicity
Plasmatic higher levels of homocysteine in Non-alcoholic fatty liver disease (NAFLD)
The Bard’s Tale
BARD
BARD
Association between PPARGC1A polymorphisms and the occurrence of nonalcoholic fatty liver disease (NAFLD)
Emerging role of nanotechnology in treatment of non-alcoholic fatty liver disease (NAFLD)
Do artificial sweeteners increase the risk of non-alcoholic fatty liver disease (NAFLD)?
Treatment of Nonalcoholic Fatty Liver Disease (NAFLD) in patients with Type 2 Diabetes Mellitus
"Endocrine NAFLD": a hormonocentric perspective of Non-Alcoholic Liver Disease (NAFLD) pathogenesis in HIV-infected patients
Korrelation von Apolipoprotein C3 und non-alcoholic fatty liver disease (NAFLD)
Indices to represent cross-sectional non-alcoholic fatty liver disease (NAFLD) and longitudinal NAFLD development during lifestyle interventions
Genetic and metabolic aspects of non-alcoholic fatty liver disease (NAFLD) pathogenicity
Plasmatic higher levels of homocysteine in Non-alcoholic fatty liver disease (NAFLD)
The Bard’s Tale
BARD
BARD
Association between PPARGC1A polymorphisms and the occurrence of nonalcoholic fatty liver disease (NAFLD)
Emerging role of nanotechnology in treatment of non-alcoholic fatty liver disease (NAFLD)
Do artificial sweeteners increase the risk of non-alcoholic fatty liver disease (NAFLD)?